Ioannis Xynos
Overview
Explore the profile of Ioannis Xynos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
1051
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abegesah A, Oh D, Lim K, Fan C, Chen C, Kim C, et al.
Cancer Chemother Pharmacol
. 2025 Jan;
95(1):23.
PMID: 39821700
Purpose: Durvalumab in combination with gemcitabine/cisplatin has shown a favorable benefit-risk profile in the TOPAZ-1 study for advanced biliary tract cancers (BTC). This analysis evaluated the population pharmacokinetics (PopPK) of...
2.
Okada M, Kato K, Cho B, Takahashi M, Lin C, Chin K, et al.
Clin Cancer Res
. 2022 Mar;
28(15):3277-3286.
PMID: 35294546
Purpose: Limited long-term data are available on immune checkpoint inhibitor use in patients with advanced esophageal squamous cell carcinoma (ESCC). We report 3-year follow-up data from our study of nivolumab...
3.
Doki Y, Ajani J, Kato K, Xu J, Wyrwicz L, Motoyama S, et al.
N Engl J Med
. 2022 Feb;
386(5):449-462.
PMID: 35108470
Background: First-line chemotherapy for advanced esophageal squamous-cell carcinoma results in poor outcomes. The monoclonal antibody nivolumab has shown an overall survival benefit over chemotherapy in previously treated patients with advanced...
4.
Kato K, Cho B, Takahashi M, Okada M, Lin C, Chin K, et al.
Lancet Oncol
. 2019 Oct;
20(11):1506-1517.
PMID: 31582355
Background: Chemotherapy for patients with advanced oesophageal squamous cell carcinoma offers poor long-term survival prospects. We report the final analysis from our study of the immune checkpoint PD-1 inhibitor nivolumab...
5.
Basset-Seguin N, Hauschild A, Grob J, Kunstfeld R, Dreno B, Mortier L, et al.
Lancet Oncol
. 2015 May;
16(6):729-36.
PMID: 25981813
Background: The Hedgehog pathway inhibitor vismodegib has shown clinical benefit in patients with advanced basal cell carcinoma and is approved for treatment of patients with advanced basal cell carcinoma for...